FDA cuts could threaten medtech innovation: Here’s why

The Trump administration’s proposed federal budget could hurt the speed and quality of FDA review times, says a top expert at Musculoskeletal Clinical Regulatory Advisers (MCRA). Glenn Stiegman, MCRA Innovation is a vital element of success for medical device companies. More than 6,500 U.S. companies are developing technologies that improve patient outcomes. This represents a

Why medtech should keep its lobbying expectations low in 2017

Political chaos means fewer opportunities for the medtech industry to get much done in Congress this year, says Clayton Hall, VP of government affairs for the Medical Device Manufacturers Assn. When it comes to permanent repeal of the 2.3% medical device excise tax that was part of the 2010 Affordable Care Act, there are fewer legislative opportunities,

Wisconsin biotech industry optimistic about state’s Foxconn win

Wisconsin’s biotech industry sees opportunity in Taiwanese electronics giant Foxconn’s decision to spend $10 billion on a 3,000-employee plant in the state’s southeast. That’s because the 8K liquid crystal display (LCD) screens made at the new Foxconn campus could enable new medical solutions for surgical procedures, according to BioForward Wisconsin. “BioForward and Wisconsin’s biohealth community welcomes

5 officials running healthcare under Trump

President Donald Trump’s critics complain that the president has yet to make hundreds of appointments to midlevel positions. But at least with healthcare, we’re starting to get a clearer picture of who is in charge. Just on May 10, the U.S. Senate confirmed Dr. Scott Gottlieb as FDA commissioner. Here are 5 top officials shaping

Pages: 1 2 3 4 5 6

The top medtech stories of early 2017

The new Trump administration and Republican Congress – and all the accompanying change and uncertainty –is the major story for the medical device industry. But there are many other medtech stories worth noting from the first quarter of 2017. There was an FDA warning over Abbott’s Absorb bioresorbable stent, a continued spate of M&A deals, a

Pages: 1 2 3 4 5 6

Trump budget would double FDA user fees

Brad Perriello, Executive Editor The Trump administration’s proposed budget, released today, would double the user fees medical device companies pay to have the FDA review the safety and efficacy of their products. The budget proposal would set user fees at $2 billion for 2018, about $1 billion more than the fee schedule for this year (annualized to correspond

Medtech stocks slump on 18% NIH cut in Trump budget plan

Brad Perriello, Executive Editor The Trump budget plan to slash more than 18% from the budget for the National Institutes of Health sent medical device stocks down today on Wall Street as investors reacted to the proposal. The budget proposal, released today, would cut the NIH budget by $5.8 billion, to $25.9 billion – an 18.3% cut.

Analysis: 5 ways Trump is making things uncertain for medtech

Want a word to sum up 2017? Try “uncertainty.” Chris Newmarker, Managing Editor Wall Street investors remain on a sugar high from the new Trump administration and Republican Congress. The Dow Jones Industrial Average is up hundreds of points since President Donald Trump’s promise to a joint session of Congress on Tuesday that he wanted to

Pages: 1 2 3 4 5 6

Trump calls for speedier approval process, while Sanders takes aim at drug prices

In his 1st address to Congress, President Donald Trump called for speeding up drug approvals within the FDA. Earlier that day, Sen. Bernie Sanders (I-Vt.) proposed a bill to allow the importation of prescription drugs from Canada in the hopes of lowering drug prices. The new administration has been critical of drug prices, with Trump saying that

Details emerge on plan to repeal, replace Obamacare

Brad Perriello, Executive Editor The evolving Republican plan to repeal and replace Obamacare would repeal cuts in payments to hospitals treating large numbers of uninsured patients, repeal the penalties for individuals and employers who don’t have or offer coverage and unwind changes to Medicaid made by the Affordable Care Act, according to a GOP policy paper issued yesterday. The

Senate confirms Price as HHS chief

The Senate confirmed Rep. Tom Price (R-Ga.) to head the Health & Humans Services Dept. in a 52-47 vote early this morning. No Democratic senator voted to support the new administration’s nominee, but he was passed through in the Republican-majority Senate. Democrats spent hours last night protesting his confirmation, pushing the vote until 2 A.M.

6 huge things you could have learned at MD&M West

A greater willingness to embrace failure and innovate—and a “yuge” elephant in the room named Donald—those are some of the major themes this week as 20,000 medical device engineers and executives meet in Anaheim, Calif., for the annual MD&M West conference and expo. Here are six things one could hear echoed throughout the expo floor and conference

Donald Trump: What medtech’s top executives are saying

For the most part, the medical device industry’s top executives have sounded positive about the new Trump administration and Republican Congress during recent earnings calls with analysts. Some such as Johnson & Johnson CEO Alex Gorsky have even offered advice. And while there are many open questions, top executives insist potential repeal and replace of

Pages: 1 2 3 4 5 6 7 8

Trump and medtech: What people in the industry think

Many MDO and MassDevice readers think permanent medical device tax repeal should be a top priority for President Donald Trump and the Republican Congress. Many say the new administration will be good for medtech, too. Those were two of the major takeaways among nearly 100 MDO and MassDevice readers responding to an online survey. There are

Healthcare industry braces for change on Trump’s executive order

President Donald Trump signed an executive order on Friday that could scale back enforcement of some provisions of the Affordable Care Act, also called Obamacare, and analysts warned that shares of hospitals and Medicaid providers could face new pressure as fears over losing coverage grow. President Trump wrote that government departments should “waive, defer, grant